Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from oman

HIGHLIGHTS

• who: Aseel A. Al-Rashdi from the We conducted a retrospective, longitudinal cohort study between January , and December During this period, a total of , patients were diagnosed with RRMS according to the revised McDonald criteria [1]. Patients were initially followed up at the neurology clinic of the Sultan Qaboos University Hospital (SQUH), a tertiary hospital in Muscat, the capital of Oman. Fingolimod therapy was initiated for all patients as a second-line therapy after failure to respond to first-line treatment prescribed by a neurologist. All of the patients fulfilled the fingolimod treatment criteria using the approved . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.